Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 374

1.

The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.

Hosoya T, Kimura K, Itoh S, Inaba M, Uchida S, Tomino Y, Makino H, Matsuo S, Yamamoto T, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H.

Trials. 2014 Jan 16;15:26. doi: 10.1186/1745-6215-15-26.

2.

Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.

Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S50-6. doi: 10.1097/RHU.0b013e31822541d0.

PMID:
21654270
3.

Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.

Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, Pandey R.

Am J Kidney Dis. 2015 Dec;66(6):945-50. doi: 10.1053/j.ajkd.2015.05.017. Epub 2015 Jul 30.

PMID:
26233732
4.

An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.

Huang X, Du H, Gu J, Zhao D, Jiang L, Li X, Zuo X, Liu Y, Li Z, Li X, Zhu P, Li J, Zhang Z, Huang A, Zhang Y, Bao C.

Int J Rheum Dis. 2014 Jul;17(6):679-86. doi: 10.1111/1756-185X.12266. Epub 2014 Jan 28.

PMID:
24467549
5.

Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.

Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S35-43. doi: 10.1097/RHU.0b013e31821d351d. Erratum in: J Clin Rheumatol. 2014 Sep;20(6):E2. Naoyuki, Kamatani [corrected to Kamatani, Naoyuki]; Shin, Fujimori [corrected to Fujimori, Shin]; Toshikazu, Hada [corrected to Hada, Toshikazu]; Tatsuo, Hosoya [corrected to Hosoya, Tatsuo]; Kenjiro, Kohri [corrected to Kohri, Kenjiro]; Toshitaka, Nakamura [corrected to Nakamura, Toshitaka]; Takanori, Ueda [corrected to Ueda, Takanori]; Tetsuya, Yamamoto [corrected to Yamamoto, Tetsuya]; Hisashi, Yamanaka [corrected to Yamanaka, Hisashi]; Yuji, Matsuzawa [corrected to Matsuzawa, Yuji].

PMID:
21654268
6.

Preservation of renal function during gout treatment with febuxostat: a quantitative study.

Whelton A, MacDonald PA, Chefo S, Gunawardhana L.

Postgrad Med. 2013 Jan;125(1):106-14. doi: 10.3810/pgm.2013.01.2626.

PMID:
23391676
7.

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.

Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.

8.
9.

Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.

Goldfarb DS, MacDonald PA, Hunt B, Gunawardhana L.

J Rheumatol. 2011 Jul;38(7):1385-9. doi: 10.3899/jrheum.101156. Epub 2011 May 15.

PMID:
21572152
10.

Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.

Tsuruta Y, Mochizuki T, Moriyama T, Itabashi M, Takei T, Tsuchiya K, Nitta K.

Clin Rheumatol. 2014 Nov;33(11):1643-8. doi: 10.1007/s10067-014-2745-5. Epub 2014 Jul 22.

11.

Febuxostat.

Hair PI, McCormack PL, Keating GM.

Drugs. 2008;68(13):1865-74. Review.

PMID:
18729537
12.

An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.

Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S13-8. doi: 10.1097/RHU.0b013e31821d36cc.

PMID:
21654265
13.

An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.

Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S44-9. doi: 10.1097/RHU.0b013e31821d352f. Erratum in: J Clin Rheumatol. 2014 Sep;20(6):E3. Naoyuki, Kamatani [Kamatani, Naoyuki]; Shin, Fujimori [corrected to Fujimori, Shin]; Toshikazu, Hada [corrected to Hada, Toshikazu]; Tatsuo, Hosoya [corrected to Hosoya, Tatsuo]; Kenjiro, Kohri [corrected to Kohri, Kenjiro]; Toshitaka, Nakamura [corrected to Nakamura, Toshitaka]; Takanori, Ueda [corrected to Ueda, Takanori]; Tetsuya, Yamamoto [corrected to Yamamoto, Tetsuya]; Hisashi, Yamanaka [corrected to Yamanaka, Hisashi]; Yuji, Matsuzawa [Matsuzawa, Yuji].

PMID:
21654269
14.

Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.

Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S19-26. doi: 10.1097/RHU.0b013e31821d36de. Erratum in: J Clin Rheumatol. 2014 Sep;20(6):E1. Naoyuki, Kamatani [corrected to Kamatani, Naoyuki]; Shin, Fujimori [corrected to Fujimori, Shin]; Toshikazu, Hada [corrected to Hada, Toshikazu]; Tatsuo, Hosoya [corrected to Hosoya, Tatsuo]; Kenjiro, Kohri [corrected to Kohri, Kenjiro]; Toshitaka, Nakamura [corrected to Nakamura, Toshitaka]; Takanori, Ueda [corrected to Ueda, Takanori]; Tetsuya, Yamamoto [corrected to Yamamoto, Tetsuya]; Hisashi, Yamanaka [corrected to Yamanaka, Hisashi]; Yuji, Matsuzawa [corrected to Matsuzawa, Yuji].

PMID:
21654266
15.

Time to target uric acid to retard CKD progression.

Kumagai T, Ota T, Tamura Y, Chang WX, Shibata S, Uchida S.

Clin Exp Nephrol. 2017 Apr;21(2):182-192. doi: 10.1007/s10157-016-1288-2. Epub 2016 Jun 23. Review.

PMID:
27339448
16.

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.

Jackson RL, Hunt B, MacDonald PA.

BMC Geriatr. 2012 Mar 21;12:11. doi: 10.1186/1471-2318-12-11.

17.

As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.

Tausche AK, Christoph M, Forkmann M, Richter U, Kopprasch S, Bielitz C, Aringer M, Wunderlich C.

Rheumatol Int. 2014 Jan;34(1):101-9. doi: 10.1007/s00296-013-2857-2. Epub 2013 Sep 12.

PMID:
24026528
18.

Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction.

Shibagaki Y, Ohno I, Hosoya T, Kimura K.

Hypertens Res. 2014 Oct;37(10):919-25. doi: 10.1038/hr.2014.107. Epub 2014 Jun 19.

PMID:
24942770
19.

Risk of Febuxostat-Associated Myopathy in Patients with CKD.

Liu CT, Chen CY, Hsu CY, Huang PH, Lin FY, Chen JW, Lin SJ.

Clin J Am Soc Nephrol. 2017 May 8;12(5):744-750. doi: 10.2215/CJN.08280816. Epub 2017 Mar 16.

20.

Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.

Fleischmann R, Kerr B, Yeh LT, Suster M, Shen Z, Polvent E, Hingorani V, Quart B, Manhard K, Miner JN, Baumgartner S; RDEA594-111 Study Group.

Rheumatology (Oxford). 2014 Dec;53(12):2167-74. doi: 10.1093/rheumatology/ket487. Epub 2014 Feb 8.

PMID:
24509406

Supplemental Content

Support Center